Daiichi Sankyo Company, Limited, recently won the “Pharma Company of the Year” award at the first “Informa Pharma Intelligence Awards”* in Japan in honor of our focus on the oncology field and the strength of our proprietary antibody-drug conjugate (ADC) platform and its broad potential for the future.
The “Pharma Company of the Year” award was given to Daiichi Sankyo based on the value of our science and technology, and ADC technology, and we believe it is a reflection of the ingenuity, challenges, and teamwork all of our employees, including those in charge of R&D.
We sincerely thank the patients and healthcare professionals who cooperate with our clinical trials and clinical studies, and all the people who support our daily activities.
Daiichi Sankyo will continue to deliver our innovative products to more patients as soon as possible through our science and technology as we continue to create innovative pharmaceuticals and contribute to the enrichment of quality of life around the world.
Pharma Intelligence Award Japan 2022 "Pharma Company of the Year" Official Banner
Dr. Sunao Manabe, President and CEO made a speech of acceptance
* Informa Pharma Intelligence Awards’ “Pharma Company of the Year” award is a Japanese version of the Scrip Awards that has been recognized worldwide for seventeen years. “Pharma Company of the Year” is given to the most prominent company in a given year.